Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

Completed · Phase 1

Conditions studied: Sickle Cell Disease, Sickle Cell Anemia

In brief

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.

Key facts

Study ID

NCT05169580

Run by

Fulcrum Therapeutics

People needed

45

Starts

2021-12-13

Expected to finish

2026-01-20

Last updated by the study team

2026-02-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Arkansas for Medical Sciences (UAMS) — Little Rock, Arkansas, United States
• University of California, Los Angeles — Los Angeles, California, United States
• Sonar Research Center — Atlanta, Georgia, United States
• University of Illinois Chicago — Chicago, Illinois, United States
• Our Lady of the Lake Hospital — Baton Rouge, Louisiana, United States
• Boston Medical Center — Boston, Massachusetts, United States
• Queens Hospital Cancer Center — Jamaica, New York, United States
• Jacobi Medical Center — The Bronx, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Eastern Carolina University — Greenville, North Carolina, United States
• Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
• University of Texas Houston — Houston, Texas, United States
• Inova Schar Cancer Institute — Fairfax, Virginia, United States
• Virginia Commonwealth University — Richmond, Virginia, United States
• National Hospital, Abuja — Abuja, Nigeria
• University of Ibadan — Ibadan, Nigeria
• Barau Dikko Teaching Hospital — Kaduna, Nigeria
• Charlotte Maxeke Johannesburg Academic Hospital — Johannesburg, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.